Judy Garber, MD, MPH

Director, Center for Cancer Genetics and Prevention

Dana Farber Cancer Institute

Dr. Garber is the Director of the Cancer Genetics and Prevention Disease Center at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. Dr. Garber conducts research in clinical cancer genetics, with a special focus in the genetics of breast cancer. She has played a major role in the development of national guidelines in cancer genetics. She is also a leader in research into the characteristics and treatment of triple negative or basal-like breast cancer, the most common form in women with BRCA1 mutations. Her translational research focuses on the evaluation of novel agents targeting DNA repair defects in breast cancer, including PARP inhibitors for treatment and prevention of breast cancer and other BRCA-associated cancers.

 In 2011-2012, Dr. Garber was the President of American Association for Cancer Research (AACR), the largest organization of cancer researchers in the world. She is a member of the National Cancer Advisory Board and was recently elected to the Institute of Medicine.

Carol Fabian, MD

Director, Breast Cancer Prevention & Survivorship Centers

KU Breast Cancer Prevention Center

Dr. Carol Fabian is a breast medical oncologist, University Distinguished Professor, and holds the Morris Endowed Chair in Cancer Prevention at the University of Kansas Medical Center.  She received her medical degree from the University of Kansas in 1972, and fellowship in Medical Oncology at the University of Kansas in 1977.  She is board certified in both Internal Medicine and Medical Oncology.  She  has been on the faculty in the Division of Medical Oncology since 1977 and has served in multiple capacities including Medical Director of the Cancer Center, Founder and Director of the Breast Cancer Prevention and Survivorship Research Center, Leader or co-Leader of the Cancer Prevention Program, and Associate Director of Clinical Research in the NCI Designated Cancer Center.

Thomas Slavin, MD, FACMG, DABMD

Senior Vice President of Medical Affairs for Oncology

Myriad Genetics

Dr. Slavin is Senior Vice President of Medical Affairs for Oncology at Myriad Genetics. He is a physician-scientist, triple-board-certified in clinical genetics, molecular diagnostics and pediatrics. Most recently, he served as assistant professor in the departments of Medical Oncology & Therapeutics Research and Population Sciences at City of Hope National Medical Center. Dr. Slavin graduated medical school with Alpha-Omega-Alpha-honors from the University of South Florida. He completed his residency programs at Case Western Reserve in Cleveland, Ohio; this training included a postdoctoral research year in genetic epidemiology. He has also completed graduate course work towards a Masters degree in clinical research through the University of Southern California. He is an active member of the American Association of Cancer Research, the American Society of Clinical Oncology (ASCO), the American Society of Human Genetics, the Collaborative Group of the Americas on Inherited Colorectal Cancer, and is a fellow of the American College of Medical Genetics and Genomics. He has served on National Comprehensive Cancer Network (NCCN)committees for both the genetics of and screening for colorectal cancer. He has served on three ClinGen expert working group committees for variant classification of breast, gastrointestinal and ovarian cancer predisposition genes. Focused on expanding genetics education for cancer care providers, Dr. Slavin has helped shape both ASCO University as well as City of Hope’s hereditary genomics training program. He is a well-published researcher in the field of medical genetics, including over 60 journal articles, multiple book chapters, and numerous presentations at national and international medical meetings. He has been involved in many national cancer research grants, and was a 2018 National Institutes of Health (NIH) K08-career development grant awardee.

Components visible upon registration.